Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-550-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) announced its quarterly earnings data on Monday, August, 5th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.35). View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
3 equities research analysts have issued 1-year target prices for Evofem Biosciences' stock. Their forecasts range from $9.00 to $11.00. On average, they expect Evofem Biosciences' stock price to reach $9.67 in the next year. This suggests a possible upside of 92.6% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.
Has Evofem Biosciences been receiving favorable news coverage?
News headlines about EVFM stock have trended positive this week, InfoTrie reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evofem Biosciences earned a daily sentiment score of 2.1 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Evofem Biosciences.
Are investors shorting Evofem Biosciences?
Evofem Biosciences saw a drop in short interest in September. As of September 30th, there was short interest totalling 783,300 shares, a drop of 6.1% from the August 30th total of 833,800 shares. Based on an average daily volume of 30,000 shares, the short-interest ratio is presently 26.1 days. Approximately 4.1% of the company's shares are sold short. View Evofem Biosciences' Current Options Chain.
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include AnaptysBio (ANAB), TherapeuticsMD (TXMD), Epizyme (EPZM), Amneal Pharmaceuticals (AMRX), Odonate Therapeutics (ODT), Y-mAbs Therapeutics (YMAB), Spectrum Pharmaceuticals (SPPI), ANI Pharmaceuticals (ANIP), Phibro Animal Health (PAHC), Athenex (ATNX), Endo International (ENDP), Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), G1 Therapeutics (GTHX) and CannTrust (CNTTF).
What other stocks do shareholders of Evofem Biosciences own?
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer (Age 49)
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Jason Abrams, Accounting Mang.
- Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $5.02.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $233.93 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.View Additional Information About Evofem Biosciences.
What is Evofem Biosciences' official website?
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
